Blood test and scan may spot hidden cervical cancer cells
NCT ID NCT03853915
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a special PET scan and a blood test for HPV can detect any remaining cervical cancer cells after standard chemoradiation. About 64 people with cervical cancer will be followed after their usual treatment. The goal is to see if these tests can predict if the cancer will come back, but no new treatment is being tested.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 64 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2019
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Histologically confirmed squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix, FIGO stage IB-IVA * 3.1.2 Planned for radical radiotherapy and concurrent cisplatin chemotherapy. * 3.1.3 Age ≥ 18 years. Exclusion Criteria: * Evidence of distant metastases (suspicious paraaortic nodes below the renal vessels allowed if they will be encompassed within the radiation field) * Patients who have received any anticancer treatment for their cervical cancer. * Other cervical cancer tumor histologies (e.g. small cell, serous) * Contraindications to 18FDG PET-CT * Contraindication to radiotherapy (e.g. severe Crohn's disease) * Contraindication to chemotherapy (e.g. non-reversible renal failure) * History of another invasive malignancy, except for non-melanoma skin cancer or tumors curatively treated with no evidence of disease for ≥ 5 years. * Known pregnancy or lactating
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cervical cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University Health Network, The Princess Margaret
RECRUITINGToronto, Ontario, M5G 2M9, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pulsed radiation extend life in metastatic cervical cancer?
- Robotic surgery vs standard approaches: does the platform change cancer outcomes?
- New antibody aims to preserve immune checkpoint while fighting cancer
- Smart speculum could bring cervical cancer screening to remote areas
- Your gut bacteria may hold the key to whether immunotherapy works
- Amazon plant put to the test against Cancer's relentless tiredness